Key Highlights

● Karyopharm traded around $0.55 at 1:05 PM ET on October 22, an intraday reading.

● The noteholder forbearance period was set to expire at 11:59 PM ET that day.

● The forbearance followed defaults under the company's loan and notes, plus a liquidity warning.

● Karyopharm is best known for Xpovio, an oral cancer drug.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) jumped on Thursday, October 22, 2026, as a forbearance agreement with the company's noteholders approached its scheduled expiry. The move made the micro-cap biotech one of the notable gainers on the Nasdaq Composite.

The stock traded around $0.55 in early afternoon, according to a 1:05 PM ET market snapshot. That is an intraday reading rather than a confirmed close. Karyopharm has a market value of roughly $8.1 million.

The forbearance deadline

According to a company filing dated October 14, Karyopharm's forbearance period with its noteholders was set to expire at 11:59 PM ET on October 22, 2026.

A forbearance agreement is an arrangement in which lenders agree, for a set period, not to exercise certain rights they would otherwise have after a default. It gives a borrower time to negotiate with its creditors.

The filing described the forbearance as following defaults under the company's loan and notes, along with a liquidity warning, according to the company. No Karyopharm announcement for October 22 itself was available, so it was not clear on Thursday whether the forbearance had been extended, amended or allowed to lapse.

Why the stock moved

No company-specific news was found to explain Thursday's rise. Stocks that trade at very low prices can swing sharply on limited information, and Thursday's gain should be read in that light rather than as a signal about the outcome of the company's talks with its noteholders.

Micro-cap stocks are often thinly traded, so relatively modest buying can push prices up quickly, and gains can reverse just as fast. With a price well below $1 a share, small changes in dollar terms translate into large swings.

About the company

Karyopharm is a commercial-stage pharmaceutical company best known for Xpovio, or selinexor, an oral cancer drug approved for certain patients with blood cancers including multiple myeloma.

The wider market

Health care was one of Thursday's strongest areas. The S&P 500 health care sector hit a record high, even though Moderna (NASDAQ:MRNA) slid after late-stage melanoma vaccine data appeared before its scheduled presentation. Several small biotech names, including Biohaven (NYSE:BHVN), MoonLake Immunotherapeutics (NASDAQ:MLTX) and Korro Bio (NASDAQ:KRRO), rallied on company-specific news.

Technology took the brunt of the selling. Heavy AI spending and negative free cash flow at Meta Platforms (NASDAQ:META), together with cautious guidance from Lam Research (NASDAQ:LRCX), triggered a rout in chip and AI shares. The Nasdaq Composite fell 694.00 points to 26,008.86, its steepest drop since June 5, and lost about $1 trillion in market value, according to market data.

Beneath the surface, the market was more balanced. About two of every three S&P 500 stocks rose, according to market reports, and the Russell 2000 index of smaller companies edged up 3.01 points to 2,784.03. Treasuries rallied, sending the 10-year yield back below a closely watched threshold for the first time since September 22.

Karyopharm's Forbearance Status Is the Key Question

The key item is any company filing or announcement on the status of the forbearance agreement now that its scheduled expiry has passed. Investors will look for detail on discussions with noteholders and on the company's liquidity position. Until more information is disclosed, the shares may remain highly volatile, as is common for micro-cap stocks facing debt-related uncertainty.